NasdaqGS:QDEL

Stock Analysis Report

Executive Summary

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology worldwide.


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Quidel's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QDEL has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.7%

QDEL

0.08%

US Medical Equipment

-2.0%

US Market


1 Year Return

48.9%

QDEL

-7.1%

US Medical Equipment

-15.1%

US Market

Return vs Industry: QDEL exceeded the US Medical Equipment industry which returned -8.2% over the past year.

Return vs Market: QDEL exceeded the US Market which returned -14.9% over the past year.


Shareholder returns

QDELIndustryMarket
7 Day0.7%0.08%-2.0%
30 Day17.2%-13.7%-19.7%
90 Day27.5%-18.1%-23.2%
1 Year48.9%48.9%-6.3%-7.1%-13.4%-15.1%
3 Year318.3%318.3%42.4%38.5%10.9%3.7%
5 Year272.0%272.0%71.1%53.4%28.4%14.4%

Price Volatility Vs. Market

How volatile is Quidel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Quidel undervalued compared to its fair value and its price relative to the market?

53.23x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: QDEL ($95) is trading above our estimate of fair value ($69.28)

Significantly Below Fair Value: QDEL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: QDEL is poor value based on its PE Ratio (53.2x) compared to the Medical Equipment industry average (37x).

PE vs Market: QDEL is poor value based on its PE Ratio (53.2x) compared to the US market (12.5x).


Price to Earnings Growth Ratio

PEG Ratio: QDEL is poor value based on its PEG Ratio (3.7x)


Price to Book Ratio

PB vs Industry: QDEL is overvalued based on its PB Ratio (7.1x) compared to the US Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is Quidel forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

14.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QDEL's forecast earnings growth (14.2% per year) is above the savings rate (1.7%).

Earnings vs Market: QDEL's earnings (14.2% per year) are forecast to grow faster than the US market (12.2% per year).

High Growth Earnings: QDEL's earnings are forecast to grow, but not significantly.

Revenue vs Market: QDEL's revenue (4% per year) is forecast to grow slower than the US market (7.1% per year).

High Growth Revenue: QDEL's revenue (4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QDEL's Return on Equity is forecast to be low in 3 years time (18.7%).


Next Steps

Past Performance

How has Quidel performed over the past 5 years?

73.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QDEL has high quality earnings.

Growing Profit Margin: QDEL's current net profit margins (13.6%) are lower than last year (14.2%).


Past Earnings Growth Analysis

Earnings Trend: QDEL has become profitable over the past 5 years, growing earnings by 73.3% per year.

Accelerating Growth: QDEL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: QDEL had negative earnings growth (-1.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (1%).


Return on Equity

High ROE: QDEL's Return on Equity (13%) is considered low.


Next Steps

Financial Health

How is Quidel's financial position?


Financial Position Analysis

Short Term Liabilities: QDEL's short term assets ($222.2M) exceed its short term liabilities ($125.9M).

Long Term Liabilities: QDEL's short term assets ($222.2M) do not cover its long term liabilities ($225.2M).


Debt to Equity History and Analysis

Debt Level: QDEL's debt to equity ratio (2.3%) is considered satisfactory.

Reducing Debt: QDEL's debt to equity ratio has reduced from 56.3% to 2.3% over the past 5 years.

Debt Coverage: QDEL's debt is well covered by operating cash flow (1062.2%).

Interest Coverage: QDEL's interest payments on its debt are well covered by EBIT (7.2x coverage).


Balance Sheet

Inventory Level: QDEL has a high level of physical assets or inventory.

Debt Coverage by Assets: QDEL's debt is covered by short term assets (assets are 17.6x debt).


Next Steps

Dividend

What is Quidel's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QDEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate QDEL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QDEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QDEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QDEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Doug Bryant (61yo)

11.08s

Tenure

US$3,421,307

Compensation

Mr. Douglas C. Bryant, also known as Doug, has been the Chief Executive Officer and President of Quidel Corp. since March 1, 2009. Mr. Bryant served as the Chief Operating Officer and Executive Vice Presid ...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD3.42M) is below average for companies of similar size in the US market ($USD5.63M).

Compensation vs Earnings: Doug's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Bryant
President11.08yrsUS$3.42m1.05% $41.9m
Randall Steward
Chief Financial Officer8.5yrsUS$1.37m0.055% $2.2m
Robert Bujarski
Senior VP of North America Commercial Operations & General Counsel14.75yrsUS$1.38m0.080% $3.2m
Werner Kroll
Senior Vice President of Research & Development5.92yrsUS$1.58m0.010% $411.0k
Michael Abney
Senior Vice President of Distribution5.25yrsUS$1.49m0.016% $630.2k
Ruben Argueta
Director of Investor Relationsno datano datano data
Ratan Borkar
Senior Vice President of International Commercial Operations2.5yrsno data0.030% $1.2m
Edward Russell
Senior Vice President of Business Development4.5yrsUS$1.11m0.041% $1.6m
Karen Gibson
Senior Vice President of Information Systems & Business Transformation1.17yrsno data0.0029% $113.4k
Phillip Askim
Secretaryno datano datano data

5.6yrs

Average Tenure

56yo

Average Age

Experienced Management: QDEL's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Douglas Bryant
President11.08yrsUS$3.42m1.05% $41.9m
Kenneth Widder
Independent Director5.42yrsUS$161.85k0.029% $1.2m
Kenneth Buechler
Independent Chairman4.67yrsUS$226.34k0.12% $4.8m
Edward Michael
Independent Director1.33yrsUS$58.35k0.0020% $79.2k
Charles Slacik
Independent Director4.42yrsUS$160.57k0.021% $826.8k
Jack Schuler
Independent Director14.17yrsUS$152.13k7.56% $300.8m
Mary Polan
Independent Director27.17yrsUS$152.13k0.068% $2.7m
Kathy Ordoñez
Director0.83yrno datano data
Matthew Strobeck
Independent Director2yrsUS$140.09k0.052% $2.1m

4.7yrs

Average Tenure

65yo

Average Age

Experienced Board: QDEL's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.5%.


Top Shareholders

Company Information

Quidel Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quidel Corporation
  • Ticker: QDEL
  • Exchange: NasdaqGS
  • Founded: 1979
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$3.979b
  • Shares outstanding: 41.88m
  • Website: https://www.quidel.com

Number of Employees


Location

  • Quidel Corporation
  • 9975 Summers Ridge Road
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QDELNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 1983
QL1DB (Deutsche Boerse AG)YesCommon StockDEEUROct 1983
QBSWOTCBB (OTC Bulletin Board)YesCommon StockUSUSDOct 1983
QL1BRSE (Berne Stock Exchange)YesCommon StockCHCHFOct 1983

Biography

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 00:31
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.